o/w40, - j health res1)_p3-23_nikom.pdftc; 17 atiul 6y711-111mn1101"2 hiv-2 1444igiffilavagi...
TRANSCRIPT
tc; 17 atiul
6Y711-111MN1101"2 HIV-2 1444IGIFfilaVAGI
/// o/W40,
3-11,VIC34 2540
fiT131111.1@lf:111h HIV-2 11.14610f.1101A1610
Prevalence of HIV-2 seropositivities among drug abusers
1Com inZi 1711111m chuqcn--1 2 avirm775^^1tll^EJ3 lstRG1117%ff1911U9fEJ 3 ttarACW11 ria-minis3
Abstract : Nikom Chaisiri, Varapan Danutra, Somchai Issaravanich, Vipa Danthamrongkul,
Vilai Chinveschakitvanich and Chanida Palanuvej. 1997. Prevalence of HIV-2 seropositivities
among drug abusers. Thai J Hlth Resch 11 (1) : 3-23.
Thailand has been an endemic area of HIV, the etiological agent of AIDS, for about the
same period as other countries. Since the infected virus is the HIV type 1 therefore the
diagnostic system has been aimed at screening for anti-HIV-1 and this may not be able to
detect the HIV-2 infected people. From the data collected by interviewing from drug abusers at
the Sarnutprakarn Province Hospital it was found that the majority of them were males (95.7%).
Anong this group, 92.9% were examined for HIV-2. Many of them came for the treatment for 1
time (50.8%). Most of them aged between 15-39 years, had low income and had only primary
school education. Nearly all of their drug used was heroin (99.6%). Upon examining the HIV-
seropositive sera (168 samples) using ELISA for HIV-2 to test for the specificity of the test kit,
81.0 percent cross reactivity were obtained. Thus an alternative strategy by screening the drug
abusers sera with an ELISA for anti-HIV1+2, confirmed with a Western blot (WB) for HIV-1
which containing gp 36 specific band for HIV-2 and reconfirmed by WB for anti-HIV-2 was
carried out. It was found that 21.2 percent of 1,152 samples were HIV seropositive and 95.5
percent of them was anti-HIV-1 seropositive whilst 3 samples (1.9%) containing both anti-HIV-1
and 2. The large number of percent cross reactivity when screening with HIV-2 ELISA in the
HIV-1 endemic area may be derived from low specificity of the viral lysate antigen. The
appearance of anti-HIV-2 among the drug abusers can be a sign of HIV-2 spread in Thailand.
Investigation into other high risk groups for HIV-2 infection, for instance, in prostitutes, is also
of important in HIV-2 surveillance.
Keywords : HIV-2, Prevalence, Drug Abuser
nwiII1S-ILF11.1 finttAcynalvitnav-ii Thalnldtmrfiutnati2
nit-Isii-Anal fitufmtnttini yolTalnitimilvitnati3
an-em'AV1v1u1magiirmalvi6
151 111‘11.111 1
m131111141014@ HIV-21.2FIGIElitn'ilqi 4
1111i0.1 2540
1111A'Otja : wlyin-ru o'mqvis-i gal:,-a1fii5g 1171 Villd1WQR 7/a eutTirrN717.75ti
UK,' 914611 14/239,1,1.771". 2540. fn1,7411VD*IVILC HIV-2 714Plf.1710IN1101 : T170'111'N'tilrU76rIa914:1-117WINSIZI
11 (1) : 3-23.
thttrAylvilrinTinovD,)/ai'a HIV 441014alivviviisIS-w-nDoinolurmi?n4igtiaiini7NnFiew7
l'i fo'715.nnoil,74,51.10 HIV-1 Idini1-711N4'unisolfAi-b. HIV 191147tIllAXPVI'M anti-HIV-1 1111.114k)
ita:-.13i@n9n-mvu HIV-2 gluitramIVIn7Pluati
47143.161 fld TI-JINE111/10194'3'01H',1, /”71.171n17 my77eitoraiod'n4114tiliOut7 J (58trat,' 95.7) ttat7unOdi,*
Liiiionmilimiionk HIV-2 92.9 71-olwraaliMni.,94?Iiiiinni rhyl oh i'avat 50.8 a'')u
7vitgaiti7:14';1N1 15-39 (2-7vi'@trat' 85.4 1404'atin 90.6)
e:tgotnigavri.waliimS-61411,utnvO'n 6otat 99.6) 714m7o7minnngolfa/41)
mrovaufmaillocni@,nimaimibm-n anti-HIV-2 Totin179.77)@iiii4s7243i1 anti-HIV (168
Tovlgibld711 ,71/ ELISA a1175J07')V anti-HIV-2 vvva)/121friluni-aulii HIV-1 ,q17.11ne.,
favot 81.0 lo/vrolgtivadiViumitilili/ J ELISA Oorn/4"1,7,1 HIV-1 1.10:,' 2 dik1111,07iiii474Nalnll
°"anon-nuoi'm Om anti-HIV-1Western blot @ ti-HIV-I itatrittnu gp 36 01147 411t'ia HIV-2 i iialnrfO 141.11
gp36 110.9 HIV-2 PlOMill461,15/1044)L171101 WB d17161./ HIV-2 NOMTNLI
IN1.14gOtTIWYVV70 1,152 anti-HIV ';'-@fliit 21.2 7144114')UlfrIfFIOLia HIV-1 aL11.71,REni-'@E18:,'
95.5 Itn1411.1a1,/.9 anti-HIV-1 118:,' 2 i'atiat' 1.9 (3 OU) n77,filifiiiitn?i-aln,,aviVIT2V HIV-2 1-01Vig
ELISA XD74/144140a' n175:,tnoTa,/ HIV-1 V.‘7 94'1V,Ifi0@1?-161@a1Mbelii114 viral lysate nnwu an
HIV-2 114PIEFILRINo'inhvtaModnilnavantisIn17/49/14@l')Tg HIV ew-ill?uth-ttrfrlyiti ni50-17n141
ri )73o-ufa HIV-2 714n4aidv,1611-eign vit,s nOani:Nia'Inet 11,9441 tliyiiiio7igdwirp/un770711:,--isynn
7n11011D.71-)50? HIV-2
g1474: IDT-/al 2, Frnkr, Pitntoaio
frnainroalremora HIV-2 luegmulOyAcl 5
ilu1fia4 2590
A _,c1:)59S.ILIJI01LSIGT/1@1@1/1111:',1J1JJA4f1141J1TVIi@[email protected] TIfIl@GlA (AIDS : Acquired
immuno Deficiency Syndrome) 4@ tfiO HIV (Human immunodeficiency virus) 1'150174 11114 Human
retroviruses '01@tj4114 Subfamily Lentivirinae (Levy, 1989) '411illtviii-i-iflujvialtrinlo) micivsai-M-Av;
ifig-mmujal4fiuunvii@l lumAtiontulfi@VI-Inuthnrogill lihianikri HIV type 1 (HIV-1) Llat
HIV type 2 (HIV-2) HIV1.1141fiail genome irwAvItij 44r114A@tjmaititi:ol d7vavitjY1-13,1Lriol
Cytopathic effect (CPE)v814 CD4+ helper T- lymphocytes
Li.lunaiwwiauilatviAl'I'Lroinyg,TrywialtalInu ji143iiu vi@h-Alimilltuuilltoili (Levy, 1986)
atilliggfInilrni-nlii4-1 HIV-2 illtutnaltD1m74ALItiLlt001,21MILDVIA.VIIDMMICA1Ell,D4
(ARC : AIDS related complex) Until-11112 GiOltn HIV-1 (Dufoort et ai., 1988; Wilkins et. al., 1993) UK
Ilfi111.111.4lAVILdri1111113Y1ILTLIIANTit-trAtkii.inflil HIV-1 (Wilkins et. a/., 1993; Poulsen et al.,
1989) ILVILemififfnILLomaill111.DGlAtIPN:SINOGi@(FIGlik11.411511.1illatilritif li'Lllilaqlk HIV-1 ttatt1uill91
1wilqo (Clavel, 1987)
luu.sitayvitru-g*NA TqluvallAlimittalttrlitillnyi-o fis'i'vbaleAoja HIV-2 ffilI1.11114 vin
ta.Moityli Immunoblot assay 1111@1' immunoprecipitation assay INIYhI111iluviait.1`401
WI HIV-2 at HIV-1 311itfriE114113.1eil,414 ll91113 411.11144131M13,1A1Antil-Mill gp 110 (outer membrane)
LL gp 41 (transmembrane) WA.1.1311grliFill'Ilf65142I@NIN:111EJ HIV-2 (Clavel et al., 1986) 11,114119811h111%
[email protected]@ ghlfleIrlIa.IN:thEAOL HIV-1 envelope protein (gp 140) '01 HIV-2
'A4 pol-encoded protein (integrase : p34):-',1411.triEnTili specific anti-HIV-2 1ALiat gag antigen RID1
HIV-1 vuloavitijazilttriitrrimilt, anti-HIV-2 p26 UM' p 25 LiAllii11111,4104{1 p 18 ':,'13:16i@EJ
anti-HIV-2 flth111 envelope 121 HIV-2 antigen 1/11.1t111E1111-11 envelope protein TN
SIV (Simian immunodeficiency virus) L'It'ilr4aly-an Llgi anti-HIV-2 rliEnAu HIV-1 LL00.9
HIV-2 LLaz,, SIV alfrmlnAloifivia.nnn-ilLezafluuLfluullultvrill HIV-2 LLat HIV-I mkynAlrrin,no
I34LarlatatIlkos110-19i1o9 Liu envelope glycoprotein, transmembrane glycoprotein UM,' gag protein flritvoqiign Liu p 15 TONI HIV-2 111.1I-lf1')1311.1141411fiAAtilfill/IN SIV LRLIlGlE17f1L1 (Cleve] et al., 1986)
HIV-2 d@l4411M,'161@t,j11.1MIAliz,'N'il-rmr)"14q)nolud-nllyq LiatkaviltiNg'ildu
11141@tj NUM) Guinea Bissau 411MEJS.19.4@l111,1i1€13-111@slith9ILTIV M2.11V1.9e1V/fLIZO LLMLOEJ@@IA1I1111 Cape
Verde Islands 1,6at Mali 0511114INVIAlniIkvi@ HIV-2 Auann iklmIllullurraviukt-A'v HIV-2 TM
Ni 11 frnalintaxema HIV-2 eitAr901Ent01401
6
r4uwo4 2640
Kanki LLarmatt luo.€1.1985 (Clavel et al., 1986) MlItilion@AD
1-35a HIV-2 6.1f11111.11/11.14 Guinea Bissau (Kanki et a/., 1985) ll.4' 14111:',1.4.1.1.14TZEJr, 2 1JCI :111.43.11 (Wilkins
et al., 1993) Llatillt,L14suriwilago)Lia HIV-2 1.W,11:1.4h"VrIfIlVIL'ili gInllVisIlglEnthantl.4 50,000 €l4 dmArrnLoArimr,alutu HIV-2 uanwrilaintittviirriniucinLLAVLEIlilthincatA ., @lion LA4frlariltulotalLiakile;,11.1')uolulruLArnlaulua gin-duLlifiLvd-1 Liu lut4-infla (Courouce et al.,
1989) ItholLna (Clavel et a/., 1986) VILGTI ,l ( Biberfeld et al., 1986) OGl1fl (Butto et a/., 1988) LLat,'Iu@aill1L1/11.1@ (0' Brien et a/., 1992)
theiiiniliiviLia HIV 1141.htlY1611014MI'91Gda HIV-1 iithEJT-sf)Lo4TitiLL-grmahttroLtuimirtialq 28 LnvilltriuLiaainvillthr,Lro LLattp-itismii LiJulloLaa9lauluLgatAninu 2527
(Anonymous, 1984) 114il'IN.€1.2528
1116,1filtrInluani@ g114',Nint.tuolEil 3 1.1 (Weniger et a/., 1991) rInnillz,i.norEILlisal'Av HIV adiliuLLIsilunaAilii-J134Ltisilunilil qiii‘"@ ,,, Liu eAoityloolo [email protected]
LwoLiJujiu Tommwitatilltisilun*.101nLvv14"111.114 HIV [email protected]'ma11J11.irm (Ni.f1.2528-2530) nhilni1CioLialiiviuLiJIAauat, 32 nitiluv-;a1LCIEJ1 8 1,k14 (urnifiN25314'1'11u-1EN 2531) (Poshyachinda, 1990) 4.1111-incnilnioism-nilknittnilbolwilnilltuiordosdaHN luei$ioAnLovolawnwnoLl1LLatilF.1, artiLwit, lui.lalflumllruivielLial-5v HIV 1A'411L1E1%1@@f111.1
61/A3.1111 .1q111 ,1 urtniniuLLatailmillAjjiNiunntwarminlunilinymtnina tratLiJullt-p-rrrokuLollth'aLLatAsIflu glaaoraurmtiouf)auLLIsmiuluvInIth lili@sNinN:91%Liad-Julvitiivihin*AuOarjluiu
wilT4LLnLiJuitivaitelui (Poshyachinda, 1990) 1.11r,LiluriwilaIN:41okLoila.ILLmalnilitstNint740,000 cm 114 .€1.2536 (Brown and Sititrai, 1994) VtliilriMIt-11;,.1111fril@OTAT1'01111.11-'1f11.4t1.1
28 qurnriutl 2538 ilN:thuavol aimIL@91Adiaufil 16,854 fiu llannE1419111k1 4,861 €44 (ill-14111 , 2538)
lullaiflutisilairrnullum1;ida HIV-2 luthr,Lvdtruatilliqn.auLiN n vn1w17tijv11LLatmlinufurmInnornslIvuol6 oni yoltpi Liataulyr1sl0141wo. 41ZoToitiIvAnAunilmt-iltuqt unvniiiu'gulrulifiN4mILLINviEl VimnItituvrrlruik,fpiG11111 (2535) 'MoilAltiN:aolmILall'[email protected] 2 .nu ViiNa1.17111i1JVIG11111014G.111alk121 HIV-1 UM 2 tlitluni7n&rAllniloda HIV-2 Liiuc5aLLInatalArilatLilo167v5alxi LoifiaaiLDun-rsOlwaLiAminuao)q, o)6S@ griardriCi '4,1111@-rantr4animurnlio)LIL1ALLUilAjf
HIV-2 It1Jio1uN5r1meiugmLilud-dly4LLA-JurinInmaanuliiilluaLginilvilaL`!4 lilt1,110Z141AEA1441 .14 (Rubsamen-Waigmann et al., 1994) llOtthtl11€1413111'114101q1@
fiuthro4uSEJLLar,thr,Lviclrikilullluknhtimilu6 Atim LiJunaluTuuiLLAlluLL+Elml-viaafiEn
-11
11 aihJil
illom 2540
frmrivriedgoAD HIV-2 luegoE3-01,147
xm5thtn@[email protected] mILL'an-nitydani'olika.nlvithtLyAli-AnfiordWiti ni1A-imAa
ctirrhadat@lmIULG HIV-2 4131miNAiiit-ulumITilltuumw1Rn7N1LattAluillw[zavalltovai
ml*n-milguviimI6iolaa HIV-2 W.11.1311:1_11JtAirrIlE114t1.61i1MILLINiSialiVtilOal1.41ht,1,11fIlieluvii@
lbl viltamilwriakialuniTd5ual5ErumllifibUlAlAndturrnmlv-nN Lot givit%ni7ilo16`6a HIV
115r,ww11.1.4oWificwi@111
Ituvri15 g15nnINLiNA voimarLo gAqi@l-A'0 HIV [email protected]@@fl ‘1,411111-1 4 ''1511‘a
villnErMilaluffiV@Iiii'3,.4Eilb ELISA (Enzyme-linked immunosorbent assay) 4.9@1",'1,111.1. ,
trloroiV@VI117011119171q anti-HIV-1 141@ q17A anti-HIV-1 at HIV-2 1.41i'@3.17% anti-HIV-1 IA@
2 vii@3116@lvtioNIVICNatrrLilatYJA94) 1.1,AWIR gUell4G17EIS WB (Western blot)
VISI.,t1Erki11.-5_nuOrY100@ll'ili-311E1Ti GPA (Gel perticle agglutination) 4.991M Anti-HIV-1
1.1,A1911RfluNjf-Ju WB
GITYLIErit ELISA 111/D GPA 1,1,P)911'A g146."144%Eyl'i IFA (Immunofluorescence assay) t211'11
WA 11,{Nal.ljiom.441mRANSiaim WB LINE V3111.111.11114
61411.11FJ1AllIffiql ELISA 11,41T11911"ArllDl LLACMR:i1PIEJ111EllAllA/li ELISA RINgT1 1-2
Tfit4A91Ilf-11441Y11111WI'NEIL INA'Ar7fi WB
wvinilk-ntuu917141 1 M-rtIVIiii'lli@mm-A11111,t@lar1J61691@ HIV-2 L4.91174111hUIRI-11D1Giltl
`111E11 ELISA HIV-1 1,1,8.% HIV-2 LIPAIRr11,4tthahEl WB '6110i1711,12-11JIllIgULWW1V110.1
V ,IilHIV-2 *11,41iAwi ra@[email protected] anti-HIV-2 iivoNTira-un-ula7,trbillalillajiii'ann
Ci rriithann 1,111114gniaAimlni@ HIV-1 lliamA:Altriti-rhJftfll HIV-2
HIV-2 l
OM
uthttymiruLLA%[email protected]
f11561G16^fau G) nniminItaitit@lk HIV-2 rAniluitlio)uVljIlinilmuip.nl@ltiull'illflql
HIV-2 11@1W,'S.1141%111 •11N1ilt1,1iFilY1E1141,414l g t.J'ALIC11,f10111141Lililt1,114141ALI (Rubsamen-Waigmann
et al., 1994) ni1A-IIRLIN@[email protected]@ HIV-2 11.411*1 U11.1iliN:7101f.111AIN F1011111@1,1t1.1:1 L Lam
uin-avroLviol.IttuLi"Nil' ilm-malkultZuficao-oLLeadi@viatium7LiviilluiormsiLkhi HIV tetUli
i'14 11 a:mil' 1 frillAnta4iioda HIV-2 lut`PqamaiNC10) 8
rruifm 2540
LLaritnii
mt, i10omiO3.1fivianth:',5)
IlsiwErrulai'lviUmplltbinilluLigia:,-%LailADA' Lair,d7wwinh=t-Lt, 8 1.18.1d'134V18@011hLasillilAwi1J
q17ilqtuvv,I, C.311@lthz,14-mi 4-5 9f713.11 LLE1112 -453,2@lIVITIAMAL g@allalih ' -lf114'141.111.11 .6141.111EJ1 (Centrifuge)
4713.1LI7 2,000 101191M-011 ttl q11.19,11-jil 4°1 vnunai 10 la oluIrwitnutaoLg@o4thantitiiiN
Lainftsi-a.o@nvm-ywnslolo-nn@o-) 41911-191tfl@ti@VIAUVIO@O 61.011.411a@ q1111,410 1.5 Na.vRuat
thr,antu 0.5 1.10. 5 vlaa) -70°
ih11.149i7LaT
ILfmnAviLLai.aitioM t@l HIV-1 u 2 IGIrlg ELISA
Vironostika HIV
Uniform II1.211Jil.411 Organon Tenikalht15101,1JOL6UN
IlfIlt,4l1,@1,41JaA 4101 HIV-2 tG1El Jfi ELISA1.4itilEJA1L4V HIV-2 ELISA KIT
Diagnostic Biotechnology ihti.vion1g1.14 Ltaraitnamald ELAVIA
Ac-Ab-Ak II
Diagnostics Pasteur I1It1YIFfr.1511,i15
911`)411,01,11111ii0ISI@ HIV-1 LLaz,' 2 101E7fi Western blot tilVIC191Th LAI anti-HIV-1
2 141
IESIA11,;11J HIV BLOT 2.2 12.11.111;11' Diagnostic Biotechnology Ihr.1,Y1FIRIgiA
lumstiA-iii,i1 .14Natrarnml@Naau kiniu HIV-1 61.41m3.13.11911,Trut 01 WHO c^7UR1aUJ'1i71111a^a1 anti
HIV-2 Ill@l111:11.4011f1lItfilL1111WilsILOall.lainlii53.11itILM1.11111 '64 1,4411,1^,11t,.11@sl HIV-2 ;10 gp 36
M7AEiti11.4g ni15J1itti1 114nItitilVitri11,riONLIM gp36 1011 Western blot HIV-2 ktinEll
&11111.1 New LAV - BLOT II 11@l1Aill Diagnostics Pasteur IlInliftWill€10
-1 .viiiii-ii7LLtlaNatl .krivilaLmni-rm,mlifs'il:109.11,14natIii@arkliliLnuntal GAG, POL LLat
ENV @t1148uti4olat 1 L11111 ?1-111011,l1111.011,11111Vidald11,911.4 indeterminate
7.1q111VANarnmurnli'mktuc:ILmsi011latl'An'a@aziavnuilatigi-olLAUTil@lfilir,g0111LOING1
Na
4-muN:t41-4415urrniny144Ciiirrii1N:illEri 1 n via@ontutinait@lmlbuif-Jatill 807
41l4 1,111.411E1 772 m LLart,* 35 f11.4 1,AuM191M661 717 qn4 (02.9%)Ltat 32 fiu (91.4%) 91- 1 3.1 -Au
is,9111-1,Iii TotillAiw-nwraiouloism [email protected]'L HIV 'V 1,152
NI 11 Wii101 1
fi1131M104.10)tia HIV-2 lutiiift1L0v4q) 9
J1Unfi4i 2540
A611114;1 1 414-)140vItilIMA6wIlY.'oviNffil°111a.ni""un-ninyi fl`gmin111E11 LOIN `-iV111.11AIED11-1a4v''Gl
valyntIllni7 LLar,11.4-niii10E1-11`ii'aill,(1ua.11917 p.n1191°R,ia HIV
/SIEJ
VI*
41147u (%) '4114')14 (%) 4111711 (%)
Lty vv717( 92.9) 32( 91.4) 749( 92.8)
55( 7.1) 3( 8.6) 58( 7.2)
113.1 772(100.0) 35(100.0) 807(100.0)
411.111.ai'a, 1113 39 1152
warmaammill
4101davmnilalz-ninir4:1,4hiumlinifwamtutna-n0ImI"Ati 911111• A A
f(1 2 LiJutokpm,nittlluni7Inifirlvim .4-1Lair)00nLihin*.m-m4nnum-lylimim-irnil INUTIMIV114111U
t.,jvsi q1U-11,01A6'-)Grii..1111avilli'umI •irn..411,iNEJ.1 1 (50.8 %) a:-,ilejviMumli'n't.illqol 6 fA:' "auar, 1.7
1,4tA'9ninnvihilimlini.19 ,iftli 2.0 G151910 q)14 91111.111 3-6 umiliUm-itiK,Lgt_mknIt-linh.rinnTualN:61En
LsyliliNitini7915-Javriniliti0 HIV-2 (1-r1Gla qm-ofii 3 411,11.4n9118lnalq 1-11141111AimlomaLo..;
ItkinilAny Itv)-i-o0-N 15-39 '11 1,11011Uat1:101
vitijAwillalq611110tiat 85A lisle 90.6 V113461h..1 d11.411441:,'S.114 q1.-1101 O IJ31%1EJ-41 61.1%) LLatilrm
Ar ynthilltnOrrffiLLan'4utaid-wou9ii-u.i.Jud'aulyitj (76.0%) 91151.111 4 4.1,0011iI@VIO1Nl'IVIEJ1101401
9114161114111:,1114 I1EJU6thJ6VA@I4 1"11Jilf:j4101E.J11,0141G1111:',31111.6q141V1111 (48.6%) 314114
71.Air11,14@liJ14filVill1114 (36.9%) vila17111-ruiws-1-1 (7.1%) vilawatiLlnu (7.4%) aatd.nalArji.lIlu
lklat4-10f1Iltilji 1,001-5,000 111Y15i@alall (58.4%) i'14114`)141..i@EJWITICIT1311-1:1NOMQ111 2101I51E116G13,11f1f17")
10,000 11111910Lk14 (13.2%) G11flE111,01,,IFIG13.̀1111I11-IN:1i11114111r,l.11Y1I'IJ411 IGLt ill.lIt51J411 (25.7%) 51.14111176gq1i
(16.0%) 111,1111 (8.7%) ,, 11 ''1411i1;9/1 (11.4%) 1,1_11-a19.4 (22.5%)
11
#111111111041011.4@ HIV-2 lutPoin411410 10
i.1141f13.1 2540
11151511 2 41latir,,1%4113.11iilfllin111411.1,141-1113.111*.IT@T411,-nlAilill41N1liltlV
4-114/ufil `nu
411r14(%)
1141
4114714(%) 41147t4(%)
inyl 1 387(50.1) 23(65.7) 410(50.8)V
5nb1 2 €111 180(23.3) 7(20.0) 187(23.2)
5r111 3 €111 73( 9.5) 4(11.4) 77( 9.5)V
4 4151 77(10.0) 77( 9.5)
St-nil 5 4151 41( 5.3) 1( 2.9) 42( 5.2)V;
5n151 6 14( 1.8) 14( 1.7)
1111 772(100.0) 35(100.0) 807( 99.9)
'1141111,9C1 5 LioollkilitztalrynlifulLvmloriauilatkwrillnin.iiN t14, 111 .Amula YJ11 J1
rVio)ni-narin,41EntilflColtraluml !amLgia:',Q41 (93.9%) milui1iNivii&It4it..11annn-i -rvifP4niUNMJ (3.6%)
vl@ cf.i (2.5%) lun116gtil LOY' -101 LIMAIVIN0161.41LITIZn4@Lalgu (99.6%) 311.4'@NI-ILIVIIEliti@UVIAIJ
1,11@F114 i.191-17111%.; 5 v).
imlini@lmItiAnLoyiLosIvriayrklinwn;'@,1 55.0%)
141193.11C1flnilfTINIlnialMS@OIL1LVYa101 1.11M111111-V1IMTLIN (26.1%) LLBLIVIiqtnivi (8.9%) 91151/11 6
LLVGAIII/ii,111.4-)1N:LMii10141147143.11n (47.0%) 3.11V1f1MalilicIM-113,11IG11@tgl'71A1,4111.1114 11,4114114'71414 (1111
23.6%) C1. 3.11airiFi7ati qi-nAtili-il VII@[email protected]'7191 (18.1%)
Namsollaki@lli'o HIV
a """,Nan1I915Ri.oulua;1691@ HIV IMN:Li17J15n1i14 - ulu 1,152 Tit,
91151/4/ 7 'ti.11141,4'ilrPoluit.vg'iimitDslilbn-inilid@QIn-i -IN:iivInLmolvrnt.n,Ani4ati @disille14'4114-Ju
(t-iti 1,113 Titi V* 39 111)
LLJ
FrnaIrrnOda HIV-2 11.4490Entthilk
ihnoal 2540
911111f; 3 AT11.11111'111:1I1T11+11,411`11' 11111.319:10i711±1111141GIEJ11,V1 461q1 411.11411G113.21N
'nu
(%)
141
(%) (%)
n. n0E-N (ill)
flryi-) 15 'II 0.7 0.7
15-19 19.0 34.4 19.7
20-24 22.5 21.8 22.5
25-29 17.2 6.3 16.7
30-34 14.1 21.8 14.4
35-39 12.6 6.3 12.3
40-44 7.0 6.3 7.0
45-49 2.2 3.1 2.3. m_ ,
50 1.14A
114 L1.1 4.7 4.5
113J 100.0 100.0 100.1
t. OtTrizmanV
IM) 61.3 56.3 61.1
0 J517 28.7 31.3 28.8
LLunfiti@ 6.2 9.4 6.3
valim/vIdi 3.1 3.1 3.8
1111 100.0 100.1 100.0
c. kiv-melnyiulqc
Il1141E1L5Ert4 2.7 3.1 2.7
tlunN 1-4 20.9 18.8 20.8
tiltnx, 5-7 22.6 18.8 22.5
8J99EJ34 1-3 32.8 31.3 32.7
ilum 5,6 LLat It-r6. 11.3 21.8 11.8
p-I'l 1h0. 2.1 2.0
ri-i'l Li E114 7.5 6.3 7.4
1111 99.9 100.1 99.9
11
1^t1 11 caluill
mi7.rinta49w1Lia HIV-2 lUej610Ent0Y41fi 12
r.1141M 2540
(insIA 4 @11.21INI.LOL'IlEJ1,P21@slr'g101E111,1'4410yOna.niiinili'111.41
111E1
(%)
14*
(%)
T.134
(%)
n. eilAnIa'ii.114
14'nLIE11,4 7.4 6.3 7.4
')111114 36.1 56.3 36.9
sliuth: .,41 19.5 28.1 48.6
11149i7F1517 7.0 9.4 7.1
113,1 100.0 100.1 100.0
T. 51EJULatiVia21-1 (1.11Y1)
< 600 1.9 0.2
600-1,000 1.4 1.2
1,001-3,000 24.4 44.2 26.9
3,001-5,000 31.1 34.6 31.5
5,001-7,000 21.0 13.5 20.0
7,000-10,000 7.8 6.9
> 10,000 14.3 5.8 13.2
1131 100.0 100.0 99.9
Fl. "7-Ti_itliteilri
iirsniirZ"1.1 26.4 25.7
!1'1211E.1 21.4 58.3 22.5
51A'1sn'ili11 16.0 16.7 16.0
1.IIMII 8.5 16.7 8.7
liuriao'iwYnR 6.2 6.1
snutiiitn-Antil 11.5 8.3 11.4
9ilvi-o141@s1141171ny.; 8.2 8.0
OW1 1.7 1.7
113J 99.9 100.0 100.1
1^YI ii Q171.,11
rtu'lm 2540
„.finaAntaviouta HIV-2 luegiglEntvrAo)
13
Nag inn1114.4oLE11 ELISA lurnImarn@lvnaut-AtialA gia HIV-1+2 Le-mlaknfiAtrzm
ELISA il g1TALL.M4F11.1a69i@ HIV-2 1,11@&l gat-11.1Alltih@EllsIfIiin,4@ HIV-2 vila HIV-1+2 To-Ailif
w:r491 2 tri1:411 LLaalli,14911111C1; 8 'ar,A141,PiiNarnIvillami anti-HIV-2 aln9i-aati4rolanu
111.1 anti-HIV-1+2 1.111.41"11@lIAIJ''Il DB (Diagnostic Biotechnology) "q t11.4Jal.n/1 81.0% d714111E.Jilla4
Vigil DP (Diagnostics Pasteur) 1VNainr1 69.6% 4111,Q111:,11N11-191'')U.1114@ q11011,gEnfil4 (matched
samples) 4114714 168 94iWr.i1.1 Dthl,Unillimlivtlicol9itilifiiquillmartio) (unmatched samples) 11141Na
6111aLgEATIS4li`ati'A4
01111.1 41 5 INOT1113.11114k1LnFloiriaukathiinili"ny
(%)
11.(0,1
(%)
1`)11
(%)
fl. anita4r,n1114uifia141,41-it imi'nbi
94.0 90.6 93.9
Naai)"1.4 3.8 3.6
2.2 9.4 2.5
1 J31 100.0 100.0 100.0
Ei164,i'6'owi51441*
1t15g14 99.6 100.0 99.6
Enu@tylkih1lAti34 0.3 0.3
0.1 0.1
1131 100.0 100.0 100.0A v s, . l', .1"
C.1,149)N811 1,11111JMI1111J1€11114
qtnlyila 87 12.9 8.9
II:Jilt:1%44@m7 26.2 22.6 26.1
na-gril1 5.4 6.4 5.4X
Viirfi@EfriEllfl 4.5 6.4 4.6
111.1111101k.1111@t@i'fl 27.6 19.4 27.3
CE.Jit-Jniu 27.5 32.3 27.7
1-334 99.9 100.0 100.0
* Inulla:!,1411.H141 601111.4TOEMIU;10ltil- li'@EJat, 69.3 u,az: 62.5 911W1G1IJ
1^Y1 11 aitnli
€1111111-1•1101qhlh HIV-2 1461GIEJ1014.10
14
r1141F11,1 2540
91111A 6 M119.4.011AS.1011-3.1110111M1N,I.101U11814101
111E1
(%)
viftl
(%)
111.1
(%)
@tjoi-Elf1'14111141.4 47.3 40.6 47.0
@fj41'̀ )E.JAVI.14111J11.4 7.6 9.4 7.7
Wil 3.8 3.6
Liuntilotj 11.6 28.1 12.3
1101G11U 6.2 6.3 6.2
N1701911E1 0,3 - 0.3
ilo-mmq)191-11 18.3 12.5 18.1
6149 4.9 3.1 4.9
100.0 100.0 100.1
01111491 7 Nan11G117Lot.i4iiial'Avi@ HIV 1,14;553.191'')U11.10M11,M14101
N8
111EJ
ELISA
'11.4-.1(0/0)
'4114114(%) 41Wn.(%)
Natrm
Nan
234(
879(
21.0)
79 0)
10(
29(
25.6)
74.4)
244(
908(
21.2)
78.8)
173!
1,113(100.0)
39(100.0) 1,152(100.0)
611514C)1 8 NamwIlaviLLau6iugAvi@ HIV-2 IGIE1[4111E..11A -11,111M1VilAIR anti-HIV-2 LG1E17 As ELISA
ELISA tiImivilla anti-HIV-1+2
Na ELISA VEJ Ilt-D1 SIN
'4114-714(%) 114714(%) '411.471,4 (%)
Ifil;'11 DB* 136( 81.0) 32( 19.0) 168(100.0)
Ifi1:411 DP 117( 69.6) 51( 30.4) 168(100.0)
*DB = Diagnostic Biotechnology, DP = Diagnostics Pasteur
10 11 0174 1 crilarisntalrewmis HIV-2 ltieFloulovAgi 15
ritiim 2540
011114;11 9 NaM191I74114E%r111VILLUtallJabi0 HIV Western blot 14.1I7Linu
1111kR1U HIV-1 une gp36 '11@1 HIV-2
V1 El 11th 1)34
U V-i aG1 dull
41U714 (%) 4114'114 (%) 41r14lu (%) 411414 (%) 4114-n4 (%)
HIV1 130(94.2) 10(83.3) 6 1 147(93.0)
HIV1+2 7( 5.1) - 7( 4.4)
Inconclusive 1( 0.7) 1( 8.3) 2( 1.3)
Negative - 1( 8.3) 1 2( 1.3)
711,1 138(100.0) 12( 99.9) 7* 1* 158(100.0)
4114-ntylaaiinii 10
crITA 9 ILmr4a-Inn-rniiialtiMAii.)ati-41%,iNainnIot,"A ELISA [email protected]
LIM4GiUD61ALL1111611.19 WB Ci9I1A HIV-1 Lo:',41Lalu gp 36 specific band HIV-2
11@liCiGIEJltaYAG) 158 f114 4•414114@HIV-1 L'INEJlad111:4En 147 4114(93.0%) 01141SM 140 f114 Linvitill 7 CIA
Tou4itainaariijiiihrismim4ourilIlublunil q) 130 gu (94.2%) tiatiqiumlu 10 4114 (83.3%) *nivItD1
ULLaNtom11%4114-114 6 Llat, 1 4114 g11341k1 d')14:1:1G11,11;@ HIV itatil'illtThnrill gp36 HIV-2 4114114
7 4114 1"111134G11111-1011.E111614111E1 DrilIlir14101@[email protected]'2Eilltii1J'[email protected],1 7 fill PH.1191 WB 1115U HIV-2
wath-lrupliblul 4 Gi'MEj10 Vint)'1.11.1111J911.11 Ilal..114114 HIV-2 oisILIvollinvicIlltii 10
91111441 10 LlMJNOr111;1. 41J14 strip 1.191 .101911R HIV-2 IS Western blot
Genome 2153.I 1 11415342 3 if514 4
GP 140 ENV + -
GP 105 ENV + +/- ++ +
P 68 POL ++ + +
P 56 GAG + +
GP 36 ENV + + + +
P 26 GAG ++ ++ ++ -
P 16 GAG + + +
caniuma Inn au
11 i01.8111 fmarcroxPoila HIV-2 11491-cutOriCm
16
iluif114 2540
1.111'.iFIN:iirl anti -HIV-2 411,171.1 3 Mi
453.11 a1N 19 Vt1114.1111N 6311 g a `1.1f1114-41/11J-11.151:113.1 6 D11fiN5iJ9141g1UP:Ifl
2 MN 38 11 011111/111N ";,1111151n11-11.1iznal 4 MilAIII1LIMIR11
;lig 3 MEI 33 CI MIllif111A1 ll111 -11% .DE1 'un - 9J5.111-137151.11.1 3 @l'AINM149111
":',V111-11PilMVITA53.1 1-3 11,CLinu 'ammia.nlivtuo-nalui .1411G:INnalaittlli ENV (GP140, 105 vila
GP 36) GAG (P56, 26 VII@ 16) Llat POL (P68) lunwillls'iniwalNatniiviarn141ouia HIV-2 d'Ait613.1 4 r,
LLnuMajinimnazi-wmo) 101EILWN -12 POL (P 68) illlnlin1.111714111d11 a4c^^11lGl7l to
Chadll'iimialN:tovli qlf'111)INM.Y11-19i@ anti-HIV anti-HIV-1 ad-ilL;in-1 '151 VIA (95.5%) lla:ilt#1
anti-HIV-1 an 2 411-rn4 3 Gll1 (1 9%)
GP 140 --
CP 105 —
P 68
P56
GP36
P 26
P16
PC NC Serum Serum Swum Serum
1 2 3 4
ITIVILLVGALLIIIINTIIMIIIM11:A .im101N:10ESILaNai ql 4 9'1'261 Iht.11.4LEIlhAF_HI4IM'5 Western
blot -/-Ttiltigyris14-11,44fitilalLatiiotathuntiith 'ilutulm-i119 `21 HIV-2 (PC = Positive control, NC =
Negative control)
NI 11 aiinl
fri3Int0444Witt HIV-2 14410%101h 17
b1t41€111 2540
Ml 'ii0L1,1i HIV 114111tLY1f1111E1133AEIMI4101.4@ 66n11411qi1JU HIV-1 lAt1.11011141.151 114
n*.rinuaatlkiirrnynlmoloutiomlilalfiu
1-33.4w-jfilaILLatwluloralnwlorti qugsa *)uniIiiovi@ HIV-2 EIllaiLimalliullut.Latfluiumlilq)Li@
34-1riau LL9iIfluviOn-ni)mnfilitullaiiiulAcknol),131 grnan']o)Ll'Illin6ii`14vvillauian1411.181 7')1A1
oisra''[email protected] HIV A11.11
HIV-2 1.14)14111utai-RtirA41.Gi
Tq)uLwNitIt.in*.ICU.19i1.1 ,1 MIl at;I:1441tiltit LIN@vaiRi@vlilm141 q)ii@ HIV-2 lUthtilifillital
Visa 6aJ n15t.g@nLainOulLov4 q1LiJunm1ati-orallwaoa,thtm5k 1.11triiILLInN:iiM1LVINCIgli1713.16AE.11
li.im511RmI5r111mal HIV-1 (Poshyachinda, 1990;
Poshyachinda, 1993) 1%11111,INIltf1111411gAli'D-A141141111aEll1,01ASWEI1111411111141.141Nlin4
IknioNTImat@luloN414319i@
vOin5u8JalN:LmO1o157a4i4vItma0141 a "IT141713.11-1011-14Y11.11,011tfi q AsI g13.1 la:11,D113.11E1 (Poshyachinda,
1993) i'Dazia-innilinihr'lli'mlN:LmAiwi loiLt.oavVnAki.in4tulsniltmvElN:ifiLii-mriurmi'atfriWilfi
EJ1Lvi4mINTIviuitriaLoo),1,vit.11wil r;11,m4iold'ulmt -jo!Jual u Lotrim qa tjluitiju LLat'iun114 41E1 i1l
unonnabiloinwirm4loElllVINi1411%1-11.htlIlf11411,1-ill
t 2527-2533 (Poshyachinda, 1990) wobyilalullaViwon-151nlurnasImIkaalo)u-nriCiormsnhtt-risu
tilfillaia.15' nuLlasnot-nTh LLatallitilkaati ( gm-41 3 at 4) 414
yn:ATrinluc-ngtlaaotitiLLatrnsilalrii.inil 4;o-)via HIV 1.1@t1 ,t4.,,a@"Rlii141.1111:21/[email protected]@iwl@t1,1 unninia HIV
34141@ 111-rnu:[email protected] (Liurri-iltut window period) LorAill
timAtILV011@[email protected],@olAvii@@inlwAitiool (ARC) LltilWVilt
@E11161114/1541M1 HIV-2 411MEJ€11GR1nrmintl51-i -lmaq tiiqICLIG1E11.1.114,01@1/1111A14114ili sl 14
(Dufoort, et a/ , 1988) Naln@limiNe:191ouiLvvolv) w.asurAPilLiwnavalnvialtia.nnymaiml
@ri111.1154 '-auvrtirm,IN:iimi tzs'li:14114-lutlAti (21.4%) fiLtwurial4i41111U N:710E11
d-Alit-AirZrollY11.1f17@lifli`)il qi144f0 [email protected] 0147E1414141@ Li14'013.11W L'Aulivg
Lorilotni-RtvrimivinfniNauinl anarmaal
NI 11 Ouil 1 friminialrent@ HIV-2 luegioltiltVINFIGI
18
ihrW134 2540
HIV-2 14-Rt1110411.411114-34aki@ @.€1.1900-1950 149i
71t.1.111.4VilliJICS1N:11'JEAlIRIN1.111.4il 1985 LL glI'AO@[email protected] oll,inhwteakiat@lrmileqi@ HIV-2 1,14
0.0.1960 til'IXIAllim.414.111.11honilqil 41iniy11,1114nalfilnAL gultiummunilli)Lf2 HIV-1 (Anonymous,
1992) @d111111oini11:',1noili@l HIV-2 @1.1.4111.4C4i@IS1114iTiviSI@SIEJ1J/l'IJIT1I1L1J1P1IN HIV-1 4.11,119ATail
LLA-Awi1ai 4 LLiin11%,'Inillial HIV-2 [email protected]@yllithr, 61(109i -11'1 1141@'1^rifl191tilait1L1EILwvil:14
alums, 4,Iii@NiUltIniT6rilsntiutnitial@lvinnil-fli,11/tD,rsutrniihwlisnuilattih.Lu-A-litual@atkatill@1
11,741111:1110A14`Walf141.11'13111170,11i11.1i1.11:if19i111.NO;lfril HIV-1 (Romieu et al., 1990;
Kanki et a./., 1994) MI1AJ1G11.41411t1.11f1911S e1 Il@lk HIV-2 114NITALat@aiim aro'iu114
101:4111_17tLIVb'141S411.?.11.411111,Y1FILLIITtililflilItIllG111@s1 1-11V-2 fl'21411filiMI1,1.1V111@1 HIV -1 (Rubsamen-
Waigmann et a/., 1994) 111,1114111-1114118ll1111111t1.1101/101 HIV-2 V171.1141.11.1 gile1"141111111171:1_11M10.1 HIV-1
IkIrli514111r11111Vii,4@t@s111 sidlt10@l1,1114111J1J1,hlf% Simon 1.1,1,'@t1tr, (1993) 1471r1IfIllil.1111414@l'A'01144i3.1
l.latl.livslifEJ(121@slegi0116 HIV-1 1/11@ HIV-2 14q113101@tiMg En1 .̂1u-kitriamut@lk HIV-2 V.; '3Uirrii HIV-1
1.rj @ltriE.11.11AULt411.41141'fidilitii3J1t1411@l '6. 11TAEJ9121144V1 CD4+ (Simon et a/., 1993; De Cock et a/., 1993)
1^41A11141.1t1.4.̀+' N,%1GAD HIV-2 tisl@lrl'41474i CD4+ 111141. @111f111 -1 500 [email protected]
HIV-1 llat HIV-2 11,41Nalm.n 1,Liivevuu HIV-1 114 peripheral blood mononucler cells (PBMC) 3.11ntri14
HIV-2 411@k1:1101Li@lli%d8:111,10111'4114-J14 CD4+ 200 [email protected]@I911 1,141^.1a1M41111')i'0114N:1_11FJ
waliu 411,6V0.1111/16111.4'h HIV-2 1.11.41.1@titunItum g@ q19i1n1 HIV -1 lii@r4:91G1v4f@EIlliq21n1vompt-11, 41 De
Cock L=iltut (1993) @SultrhuNadJumi;r4afi HIV-2 1,1.1giaRnr,i11011:i4MILLatalitt.I.IrVIAGiEnnni
HIV-1 OdUrnl'iivAaLiimmnmflvii@nIlult-huralvtfuri qjmnoLiJuk wil.ii,INImI'9)i)Cia HIV-2 iitITInD
Si@ilm7137:a4411,4114.1oli"
Lmit-i-1411.4-An3114'@u LivinmavitajailfilWriVatjuatN:91iiSsvatii-isA'o)00,14
vnfilmwos0
a7;11 ELISA ifielifLiityreio-S;91 anti-HIV-2 lairmin-An1N
Toluvil@tauii-26,14534C,1Liq.av'INau-miLLA'') (HIV-positive samples) iiibiltriA171.1, '211111;11 DB
114,1auln 136 9i0@d14n1f1 168 G17Edms1 (81.0%) tor,SiamilauAltralul ELISA aintii-k' DP ei,vNainn
117 G1JEEi15 (69.6%) laGE.11,1491111.1=1/0111E1/111 j IMEI1J711-1D`klil HIV-2 1:',u1o841n-i@14
Natnnii@ HIV-2 [email protected]%11@l1311V114"Attf-1011-1MIS1011tiliE11°1113.1 (cross reactivity)
1%11til a anti-HIV-2 1,1445a.1 (61101 false positive) 0i1111111YINalS741@s11111 -Zi1qi1e143.1111 (81.0%
69.6%) WV11`i11,11EJTIJNLII DB 1,N1tItilityrtmLifin - aiUlt@slifil:4111 DP 1,1-,ImaiNii141,1,@14'ilM4 '6.401
viral lysate aln HIV-2 flUSIMTk.1141f1111,91StAILL@Ia6314L1U1411,11 g14IA1144V (Liu JS Recombinant
DNA)1,14n -nmiumivaunIttincl HIV-1 1511111h0 ELISA A-11611517A HIV-2 ilflmaAincra@util
11 QLSJYI 1 frnmIntalepowin HIV-2 ItiFMEAMAqi
19
ril41M 2540
false positive 3.nriNiU11114L111,1LIAIllr,l121461M4 HIV-2 11181Enradaliltil 'iMihN'NU anti-HIV-1 1140911,b@
HIV-1 (Clavel, '1987)
lumIgimn7aln-116w4favim'f-Jadllii3.1 1,152 11E1 thinCti3IN:1.01Aiii010,ViNau7rwiaMIViTh@LI
anti-HIV-1+2 46tli5@Uar, 21.2 tiLiJufillnkhetifiToArit@lnolk HIV-1 1,14010E110140411,Lqi
Lial.411@111111:[email protected] q'111.1,911“1.2531 611N.0.2533 (Poshyachinda, 1990) LLM'ilglillilf1713.1
LIJAminlasnalmIWAa.nn i1nmliii1617-imlioniaNCialattri qR-inivmNa 2 thtnil thtm11111-1
a-RINN11-1fIrn711115141,17,1@@lfil411CL@OlA'34-414LiatLiNa'41 MIIn.110111@1 gall% iii3ALLaLfluNoTawal
itatgiotiaCiiikinmIlIRtilq111,i11,4t,I,610-1111,01^,A01-1Eltrimial15:,'MIC10@lhRinm1911,4almajLi-141L4aul
`,11,1-11,1,1A4n--141-ywiut`ilf111.TIALgEleillgITIlh.lf1; LA1E1011R tkaz;
vit-Anlutalw:Ln9lqiN111,14.1a1,03.1
11.4t-nwilwAatitiNinl'41Ria HIV LIE1141111t11 WB '[email protected] HIV-1 ilflunu
36 11@1 HIV-2 (HIV-2
specific band) 1`33J2E,j4i'M HIV-1 ISIEJlti-Ulkl-Anuat 93.0 LLatalml'&da HIV-2 TA!
atjfiu HIV-1 '41147L4 7 TILI LlUrla@l111I1011,1,t111 g gp36 121 HIV-2 &WW1 tairmilillAvilLitufm
HIV-2 V1S@UU 411111,0111fIllfil-Vii410E;1;11101 WB anti-HIV-2 IA4@Gyililq
1,[email protected];1'1,Wil1 61 F11119113.141011/11401141@ l31 "1/11111AtiltIl WB DP MAI 3 114 791@J
I, IRih@EllYiTalAill&a.1719i8 anti-HIV-2 .;Ii@rILLI-Iiint@l Env, Pol, UM,' Gag 41@"Nl'Illv'ti`i11111-111A15R0,10
fr113.11/1`211-117 -111,4@ HIV-2 1.14001EW11910C11 3.11i1111191111AiLlilltall4U0y1111711111 1,152 110 1q1tirm1,4i
ELISA WB flr4:71064@ HIV-2 114'11.4 3 11E1 4111111%1AILTI gIg 11111t11111414Til LIA-111 gp 36
fthin,126,l'olvaar,LiJukai-i-Sin141, 1t;a HIV-2 *14 oisnl'umwyNauu,a1.441uag61, 2,1:
giD HIV-2 ":.,'91@,961,1114-itywnRoau WB LWAFIVil@l HIV-2
adiAltillum11•4tifilitrt.nt mIlliyioatiV11111,61J11Wii1J1716A91TAYi'711.11.1.A11.1b)liMIT(ibAfill' '
@l4E.11111E1111,1571.1k61.411-bAZ;1124Q11 -13.11:[email protected]'Edufil?)iroinn9io HIV-2 Anian-ia.ni-ittlrolau
LiN3-11,613.1IGIEATAW-l gfl T1111-111@lifWEIll'7153.11,1JY11 neutralization test fill 11 'i HIV-2
3.111,11.11-1l@1115 HIV 11_11/1110i1J1.1JV 4.11SmilvailumIAny1uLoxiAn tlatkla-AutlifilfimILLuril)5aan
111110@l_I gfAlEJ 131@lillf11111@[email protected]@till
LiatviiltiNAA'cQi.luz`ium161@da HIV-2 114111:016/Eli@l41q191A'IATIA
11-1114111filil anti-HIV-2 114114N:610EJ11,M41. 01,1114611@li,11J@TIT11114111,11I1D1 HIV-2 1141_11:,Titlailtilik)
filliGlii@f4MINUll!JUMIOLi@ HIV 11.9 2 `Ifilq111,1filA si 411,111.4
HIV-1 1,Al`d106Au-Alith.4N:91ovi@haotlivilalli uanvindmI
011114141akidlun4L&Awi 1,9114 n*.antit,
11 OA
frnanintavma HIV-2 14100-WY& 20
rM141M 2540
LiiNvinn-n-vi9)0@ukalhaoulSitivilmIliulwi'litivtiilim 4nt-11o1Li@ HIV INU'ilihIlsql'')@tflIdha
Lid-131 HIV-2 1,1,111@0,14VItil:J@AVALLAAlhaEllill4
NalolmIlitx)iAimriA'Afiofiin11111.41.1h1INMII:11.11011@li:ia HIV-2 1141J5t alolvitiVviaiErk
4iaLLInfA alm11:111011@sl HIV-2 1,[email protected] atataliumAmtnfivauulutuLk fm`lvlu
lriuk HIV-2 "It-l01,01 4115M.N:',41@sInULMtV1141@lda91@lil
HIV-2 1%1'1 3 Tin
(115 15 J^l^1^flf1s^J 11^t1J5^61UE1ltVlSa 6&! ol@v2thl-u-kiShamsfiotiityAin'614Lgu vl5aain6v 5n1
Agloinisanl l:rno
vituttrAutali@uf;ntivlialnIdarvi lviulAuitiAlul uilsolh'imnoNT.Tris ola evuotitimIliuA
qpoNAno lAutlonuI 61t166@@IJINI
inblei Lot qpi.ntiN LIZREj arrimmtal
orniVAulvuici q4mILLIAME‘fitik1EAUMILAIA'[email protected] anA3.,mblglystilitimlinwiAc)Oloaa qi 10
Lkutuslinl ."'gEJ61,n°11@t@IMN qp')'141,1g1% i'll‘li1E11,11F111171114J114q111611,Lat110.9114N'ELI4A11.1
as,o'hug
U1413.11.41141C1
ay155t-14, '1.4111111,1•141
20141'11 Olf fill
voqmvit
DilNnIn1
11.31t11'),
43.1avvri
LIIIN1711711114111A
UJaS r@eil
1.9411..10
n frIMATItOlqd@ HIV-2 14101ntOYAG) 21
11141C34 2540
Lanoilt-Al
il114134. 2538. gIlianUrnIntlIKUA NI 26 (2) nallniorlviui
1-17tyn-Ammlutqt 3 1,11410X1 V11,11 13-24.
frimn 0-4.66 2535. 1117111:13.1LMI41 I,101 grriOtorianin5AltiolaJnisInnouitIRLEoA 410g4ILLat
ll%119114t@WIRVi 27-29 G.1810,11 2535 111111E11-111151111.qt Lowt-ntiuliulviEnoim-147-movviti
-114-1alnulawnlylEnk
Anonymous. 1984. Weekly Epidemiological Survillance Report of Thailand. 15: 509 - 512.
Anonymous. 1992. HIV-2 Update. In Focus Genetic System Corporation Summer Issue. p11.
Biberfeld G., Bottiger B., Bredberg-Raden U., Pulkomen PO., Ericsson L., Berglund 0., Stamp C.
and Hakansson C. 1986. Findings in four HTLV-IV seropositive women from West Africa.
Lancet 2 (8519) : 1330-1331.
Brown T. and Sititrai W. 1994. Estimates of HIV infection levels in the Thai population. Tenth
International Conference on AIDS, Yogohama, Japan 7-1 August 1994 Abstract No.182C.
Butto S., Verani P., Rezza G., Sernicola L., and rossi GB. 1988. Simultaneous seropositivity to
HIV-1 and HIV-2 in Italian drug abusers. AIDS 2 139-140.
Clavel, F. 1987. HIV-2, The West African AIDS virus. AIDS 1 135-140.
Clavel F., Guetard D., Brun-Vezinet F., Chamaret S., Rey MA., Santos-Ferrera MC., Laurent AG.,
Dauguet C., Katlama C., Rouzioux C., Klatzmann D., Champalimaud JL., and Montagnier L.
1986. Isolation of a new human retrovirus from West-African patients with SIDS. Science
233: 343-346.
N11 11 altil 1
vmairrgalejulA@ Hiv-21140ou1orik 22
r0414-11.1 2540
Courouce AM., Barin F., Baudelot J., Chamret S., Gueguen M., Janot C., Lemaire JM., Maniez M.,
Mesnier F., Mouillot L., et. a/. 1989. HIV-2 infection among blood donors and other subjects
in France. The Retrovirus Study Group of the French Society of Blood Transfusion.
Transfusion 29(4) : 368-370.
De Cock KM., Adjorlolo G., Ekpini E., Sibailly T., Kouadio J., Maran M., Brattegaard K., Vetter KM.,
Doorly R. and Gayle HD. 1993. Epidemiology and transmission of HIV-2. Why there is no
HIV-2 pandemic. JAMA 270 (17): 2083-6.
Dufoort G., Courouce AM., Ancelle PR. and Bletry 0. 1988. No clinical signs 14 years after HIV-2
transmission via blood transfusion. Lancet 2 (8609) : 510.
Kanki PJ., M'Boup S., Ricard D., Barin F., Denis F., Boye C., Sangare L., Travers K., Albaum M.,
Marlink R., Romet-Lemonne JL., and Essex M. 1987. Human T-lymphotropic virus type 4
and the human immunodeficiency virus in West Africa. Science 236: 827-831.
Kanki PJ., Mclane FF., King NW. Levin NL., Hunt R.D. and Sehgal P. 1985. Serological
identification and characterization of a macaque T-lymphotropic vetrovirus closely related
to HTLV-III Science 228: 1129-1201.
Kanki PJ., Travers KU., MBoup S., Hsieh CC., Marlink RG., Gueye N., Diaye A., Siby T., Thior I.,
Hernandez-Avila M., Sankale JL. et al. 1994. Slower heterosexual spread of HIV-2 than HIV-
1 Lancet 343 (8903): 943-946.
Levy JA. 1986. The multifaceted virus. Cancer Research 46 5457-5468.
Levy JA. 1989. The human immunodeficiency viruses: detection and pathogenesis. In AIDS:
Pathogenesis and Treatment. Levy JA. ed. NY Marcel Dekker Inc. New York. p159-230.
O'Brien TR., George JR. and Holmberg SD. 1992. Human immunodeficiency virus type 2 infection
in the United States : epidemiology, diagnosis and public health implications. JAMA 267:
2775-2779.
friluisrmalrFiovia HIV-211,0)InorAo 23
1110€13.1 2540
Poshyachinda V. 1990.Overview of human immunodeficiency virus infection in Thailand : A
concise review of status and epidemiology. Institute of Health Research, Chulalongkorn
University. Presented at the Meeting of Working Group and HIV Infection and Drug Abuse
in the Western Pacific Region 15-19 October. Kuala Lumpur, Malaysia.
Poshyachinda V. 1993. Drug injecting and HIV infection among the population of drug abusers in
Asia. Bulletin on Narcotics XLV (1): 77-90.
Poulsen AG., Kvinesdal B. and Aaby P. 1989. Prevalence of and mortality from human
immunodeficiency virus type 2 in Bissau, West Africa. Lancet 1: 827-830.
Romieu I., Marlink R, and Kanki P. 1990. HIV-2 link to AIDS in West Africa J. Acquir Immune
Defic Syndr 3: 220-230.
Rubsamen-Waigmann H., Maniar J., Gerte S., Brede HD., Dietrich U., Mahambre G., and Pfutzner
A. 1994. High proportion of HIV-2 and HIV-1/2 double-reactive sera in two Indian states,
Maharashtra and Goa : First appearance of and HIV-2 epidemic along with an HIV-1
epidemic outside of Africa. International Journal of Medical Microbiology, Virology,
Parasitology & Infectious Diseases 280: 398-402.
Simon F., Matheron S., Tamelet C., Loussert-Ajaka I., Bartezak S., Pepin JM., Dhiver C., Gamba E.,
Elbim C., Gastaut JA., Simot AG., and Brun-Vezinet F. 1993. Cellular and plasma viral load
in patients infected with HIV-2. AIDS 7 1411-1417.
Weniger BG., Limpakarnjanarat K. and Ungchusak K. 1991. The epidemiology of HIV infection and
AIDS in Thailand. AIDS 5: 571-585.
Wilkins A., Ricard D., Todd J.,Whitle H., Dias F. and Da Silva AP. 1993. The epidemiology of HIV
infection in a rural area of Guinea-Bissau. AIDS 7 : 1119-1122.